AI Engines For more Details: Perplexity Kagi Labs You
Hypertension (High Blood Pressure): Lisinopril is commonly prescribed to lower blood pressure in individuals with hypertension. By relaxing blood vessels, it helps to reduce the workload on the heart and decrease blood pressure.
Heart Failure: Lisinopril is used in the management of heart failure, a condition in which the heart is unable to pump blood effectively. It helps to improve symptoms, reduce hospitalizations, and prolong survival in individuals with heart failure.
Heart Attack: After a heart attack, lisinopril may be prescribed to improve survival and reduce the risk of future cardiovascular events. It helps to prevent further damage to the heart and may improve heart function.
Diabetic Nephropathy: Lisinopril has been shown to be effective in slowing the progression of diabetic nephropathy (kidney damage caused by diabetes) in individuals with type 1 or type 2 diabetes. It helps to protect the kidneys by lowering blood pressure and reducing strain on the kidneys.
Chronic Kidney Disease: In individuals with chronic kidney disease, especially those with proteinuria (excess protein in the urine), lisinopril may be prescribed to help slow the progression of kidney damage and reduce the risk of complications.
Left Ventricular Dysfunction: Lisinopril may be used to improve left ventricular dysfunction, a condition in which the left ventricle of the heart does not pump blood effectively. It helps to improve heart function and reduce symptoms such as shortness of breath and fatigue.
Coronary Artery Disease: Lisinopril may be prescribed as part of the treatment plan for individuals with coronary artery disease to reduce the risk of cardiovascular events and improve outcomes.
Stroke Prevention: In some cases, lisinopril may be used for stroke prevention, especially in individuals with hypertension or other risk factors for stroke.
Systolic Dysfunction: Lisinopril is sometimes used to treat systolic dysfunction, a condition in which the heart's ability to pump blood is reduced. It helps to improve heart function and reduce symptoms.
Other Cardiovascular Conditions: Lisinopril may be prescribed for other cardiovascular conditions as determined by a healthcare professional.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
ADHD | 0.1 | 0.3 | -2 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
Allergic Rhinitis (Hay Fever) | 0.2 | 0.4 | -1 |
Allergies | 0.8 | 0.8 | |
Allergy to milk products | 0.4 | 0.2 | 1 |
Alzheimer's disease | 0.3 | 0.7 | -1.33 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.4 | -1 |
Ankylosing spondylitis | 0.5 | 0.5 | |
Anorexia Nervosa | 0.1 | -0.1 | |
Antiphospholipid syndrome (APS) | 0.4 | 0.2 | 1 |
Asthma | 1 | 0.1 | 9 |
Atherosclerosis | 0.4 | 0.1 | 3 |
Atrial fibrillation | 0.3 | -0.3 | |
Autism | 1.1 | 0.8 | 0.38 |
Autoimmune Disease | 0.2 | 0.1 | 1 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Biofilm | 0.4 | 0.4 | |
Bipolar Disorder | 0.6 | 0.3 | 1 |
Brain Trauma | 0.1 | -0.1 | |
Breast Cancer | 0.4 | 0.4 | |
Carcinoma | 0.6 | 0.6 | |
Celiac Disease | 0.4 | 0.2 | 1 |
Cerebral Palsy | 0.1 | -0.1 | |
Chronic Fatigue Syndrome | 1.2 | 0.3 | 3 |
Chronic Kidney Disease | 0.5 | 0.2 | 1.5 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.1 | 3 |
Chronic Urticaria (Hives) | 0.5 | 0.5 | |
Coagulation / Micro clot triggering bacteria | 0.5 | 0.1 | 4 |
Cognitive Function | 0.1 | -0.1 | |
Colorectal Cancer | 0.6 | 0.4 | 0.5 |
Constipation | 0.2 | 0.1 | 1 |
Coronary artery disease | 0.5 | 0.1 | 4 |
COVID-19 | 1.4 | 0.3 | 3.67 |
Crohn's Disease | 1 | 0.1 | 9 |
cystic fibrosis | 0.5 | 0.1 | 4 |
d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
deep vein thrombosis | 0.5 | 0.1 | 4 |
Depression | 1.6 | 0.4 | 3 |
Eczema | 0.2 | 0.2 | |
Endometriosis | 0.5 | 0.4 | 0.25 |
Epilepsy | 0.5 | 0.5 | |
erectile dysfunction | 0.2 | 0.2 | |
Fibromyalgia | 0.3 | 0.3 | |
Functional constipation / chronic idiopathic constipation | 0.5 | 0.1 | 4 |
gallstone disease (gsd) | 0.5 | 0.1 | 4 |
Generalized anxiety disorder | 0.8 | 0.8 | |
Graves' disease | 0.1 | -0.1 | |
Hashimoto's thyroiditis | 0.1 | 0.2 | -1 |
Heart Failure | 0.5 | 0.1 | 4 |
Hidradenitis Suppurativa | 0.2 | 0.2 | |
High Histamine/low DAO | 0.4 | 0.4 | |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
hyperglycemia | 0.5 | 0.5 | |
Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 0.2 | 0.4 | -1 |
Hypothyroidism | 0.3 | -0.3 | |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 0.3 | 0.1 | 2 |
Inflammatory Bowel Disease | 1.5 | 0.8 | 0.88 |
Insomnia | 0.1 | -0.1 | |
Intelligence | 0.4 | 0.4 | |
Irritable Bowel Syndrome | 0.6 | 0.1 | 5 |
ischemic stroke | 0.4 | 0.2 | 1 |
Liver Cirrhosis | 1.2 | 0.6 | 1 |
Long COVID | 0.5 | 0.2 | 1.5 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 0.3 | 0.3 | |
Lymphoma | 0.2 | 0.2 | |
Mast Cell Issues / mastitis | 0.2 | 0.2 | |
ME/CFS without IBS | 0.8 | 0.8 | |
Menopause | 0.1 | -0.1 | |
Metabolic Syndrome | 1.4 | 0.4 | 2.5 |
Mood Disorders | 1.2 | 0.5 | 1.4 |
Multiple Sclerosis | 1.2 | 0.1 | 11 |
Multiple system atrophy (MSA) | 0.1 | 0.1 | |
myasthenia gravis | 0.2 | 0.1 | 1 |
neuropathic pain | 0.3 | 0.2 | 0.5 |
Neuropathy (all types) | 0.3 | 0.2 | 0.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.1 | 5 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | |
Obesity | 0.9 | 0.3 | 2 |
obsessive-compulsive disorder | 0.5 | 0.5 | |
Osteoarthritis | 0.2 | 0.2 | |
Osteoporosis | 0.5 | 0.5 | |
Parkinson's Disease | 1 | 0.2 | 4 |
Polycystic ovary syndrome | 0.2 | 0.2 | 0 |
Psoriasis | 0.4 | 0.1 | 3 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.1 | 6 |
Rosacea | 0.1 | -0.1 | |
Schizophrenia | 0.4 | 0.1 | 3 |
scoliosis | 0.4 | 0.2 | 1 |
Sjögren syndrome | 0.2 | 0.2 | |
Sleep Apnea | 0.3 | -0.3 | |
Slow gastric motility / Gastroparesis | 0.4 | 0.4 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
Stress / posttraumatic stress disorder | 0.4 | 0.6 | -0.5 |
Systemic Lupus Erythematosus | 0.6 | 0.1 | 5 |
Type 1 Diabetes | 0.3 | 0.1 | 2 |
Type 2 Diabetes | 1 | 0.4 | 1.5 |
Ulcerative colitis | 0.5 | 0.4 | 0.25 |
Unhealthy Ageing | 0.4 | 0.1 | 3 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]